Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:22:54.484Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:22:54.484Z.
Quote observation: 2026-10-06T18:16:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 680db3c2305e98602fe5277f15244516f30a0ab53cbf5830e5b41f5092839f7c
FORWARD PE RATIO
N/A
SL Science Holding Ltd
Market Cap
$855.16M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| SL Science Holding Ltd (SLBT) | $855.16M | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $855.71M | N/A |
| SI-BONE, Inc. (SIBN)vs › | $857.72M | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $861.64M | 13.58 |
| QuidelOrtho Corporation (QDEL)vs › | $841.14M | 15.96 |
| Beta Bionics, Inc. (BBNX)vs › | $841.08M | N/A |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.01M | N/A |
| Alumis Inc. (ALMS)vs › | $837.93M | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $873.28M | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $836.41M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
